Literature DB >> 17959370

Fragment-based approaches to enzyme inhibition.

Alessio Ciulli1, Chris Abell.   

Abstract

Fragment-based approaches have provided a new paradigm for small-molecule drug discovery. The methodology is complementary to high-throughput screening approaches, starting from fragments of low molecular complexity and high ligand efficiency, and building up to more potent inhibitors. The approach, which depends heavily on a number of biophysical techniques, is now being taken up by more groups in both industry and academia. This article describes key aspects of the process and highlights recent developments and applications.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17959370      PMCID: PMC4441723          DOI: 10.1016/j.copbio.2007.09.003

Source DB:  PubMed          Journal:  Curr Opin Biotechnol        ISSN: 0958-1669            Impact factor:   9.740


  51 in total

1.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening.

Authors:  Susan L McGovern; Emilia Caselli; Nikolaus Grigorieff; Brian K Shoichet
Journal:  J Med Chem       Date:  2002-04-11       Impact factor: 7.446

2.  The consequences of translational and rotational entropy lost by small molecules on binding to proteins.

Authors:  Christopher W Murray; Marcel L Verdonk
Journal:  J Comput Aided Mol Des       Date:  2002-10       Impact factor: 3.686

3.  A 'rule of three' for fragment-based lead discovery?

Authors:  Miles Congreve; Robin Carr; Chris Murray; Harren Jhoti
Journal:  Drug Discov Today       Date:  2003-10-01       Impact factor: 7.851

Review 4.  Small-molecule inhibitors of protein-protein interactions: progressing towards the dream.

Authors:  Michelle R Arkin; James A Wells
Journal:  Nat Rev Drug Discov       Date:  2004-04       Impact factor: 84.694

Review 5.  Fragment-based lead discovery: a chemical update.

Authors:  Daniel A Erlanson
Journal:  Curr Opin Biotechnol       Date:  2006-11-03       Impact factor: 9.740

6.  Identification of novel fragment compounds targeted against the pY pocket of v-Src SH2 by computational and NMR screening and thermodynamic evaluation.

Authors:  Jonathan D Taylor; Philip J Gilbert; Mark A Williams; William R Pitt; John E Ladbury
Journal:  Proteins       Date:  2007-06-01

7.  The additivity of substrate fragments in enzyme-ligand binding.

Authors:  T J Stout; C R Sage; R M Stroud
Journal:  Structure       Date:  1998-07-15       Impact factor: 5.006

8.  Application of fragment screening by X-ray crystallography to beta-secretase.

Authors:  Christopher W Murray; Owen Callaghan; Gianni Chessari; Anne Cleasby; Miles Congreve; Martyn Frederickson; Michael J Hartshorn; Rachel McMenamin; Sahil Patel; Nicola Wallis
Journal:  J Med Chem       Date:  2007-02-22       Impact factor: 7.446

9.  Probing hot spots at protein-ligand binding sites: a fragment-based approach using biophysical methods.

Authors:  Alessio Ciulli; Glyn Williams; Alison G Smith; Tom L Blundell; Chris Abell
Journal:  J Med Chem       Date:  2006-08-10       Impact factor: 7.446

10.  pH-tuneable binding of 2'-phospho-ADP-ribose to ketopantoate reductase: a structural and calorimetric study.

Authors:  Alessio Ciulli; Carina M C Lobley; Kellie L Tuck; Alison G Smith; Tom L Blundell; Chris Abell
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2007-01-16
View more
  36 in total

Review 1.  Adenylating enzymes in Mycobacterium tuberculosis as drug targets.

Authors:  Benjamin P Duckworth; Kathryn M Nelson; Courtney C Aldrich
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

2.  Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery.

Authors:  Hernani Leonardo Silvestre; Thomas L Blundell; Chris Abell; Alessio Ciulli
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-19       Impact factor: 11.205

3.  A three-stage biophysical screening cascade for fragment-based drug discovery.

Authors:  Ellene H Mashalidis; Paweł Śledź; Steffen Lang; Chris Abell
Journal:  Nat Protoc       Date:  2013-10-24       Impact factor: 13.491

4.  The multiple roles of computational chemistry in fragment-based drug design.

Authors:  Richard Law; Oliver Barker; John J Barker; Thomas Hesterkamp; Robert Godemann; Ole Andersen; Tara Fryatt; Steve Courtney; Dave Hallett; Mark Whittaker
Journal:  J Comput Aided Mol Des       Date:  2009-06-17       Impact factor: 3.686

Review 5.  X-ray crystallography over the past decade for novel drug discovery - where are we heading next?

Authors:  Heping Zheng; Katarzyna B Handing; Matthew D Zimmerman; Ivan G Shabalin; Steven C Almo; Wladek Minor
Journal:  Expert Opin Drug Discov       Date:  2015-07-15       Impact factor: 6.098

Review 6.  Enzymatic transition states, transition-state analogs, dynamics, thermodynamics, and lifetimes.

Authors:  Vern L Schramm
Journal:  Annu Rev Biochem       Date:  2011       Impact factor: 23.643

Review 7.  The rise of fragment-based drug discovery.

Authors:  Christopher W Murray; David C Rees
Journal:  Nat Chem       Date:  2009-06       Impact factor: 24.427

8.  Route to three-dimensional fragments using diversity-oriented synthesis.

Authors:  Alvin W Hung; Alex Ramek; Yikai Wang; Taner Kaya; J Anthony Wilson; Paul A Clemons; Damian W Young
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-11       Impact factor: 11.205

9.  Discovery of fragment molecules that bind the human peroxiredoxin 5 active site.

Authors:  Sarah Barelier; Dominique Linard; Julien Pons; André Clippe; Bernard Knoops; Jean-Marc Lancelin; Isabelle Krimm
Journal:  PLoS One       Date:  2010-03-17       Impact factor: 3.240

10.  A mapping of drug space from the viewpoint of small molecule metabolism.

Authors:  James Corey Adams; Michael J Keiser; Li Basuino; Henry F Chambers; Deok-Sun Lee; Olaf G Wiest; Patricia C Babbitt
Journal:  PLoS Comput Biol       Date:  2009-08-21       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.